Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More

L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.

Thayer Line
L’Oreal adds to its portfolio the Thayers Natural Remedies line, which it says appeals to consumers on two key skincare trends, nature and health.

Following delays due to the COVID-19 pandemic, China’s State Council made the country’s updated cosmetics rules official, putting foreign companies on an equal playing ground with domestic entities and emphasizing a risk-based approach to regulation. The State Council approved the Cosmetics Supervision and Administration Regulation in January, revising its framework to align closer with cosmetics regulations in other modern countries. (Also see "Cosmetics Industry Awaits ‘Critical’ Safety Assessment Clarification Under China’s New Framework Reg" - HBW Insight, 24 February, 2020.) It published the text for the regulation on 29 June. Under the rules which go into effect in January 2021, manufacturers will be responsible for registration, product safety, quality and efficacy, and penalties will be imposed on those who are noncompliant.

Attorney Katherine Wang, a partner with Ropes & Gray LLP in Shanghai, says firms using new cosmetic ingredients may receive...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Deals

Nancy Tests Arc AI Editor

 
• By 

Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

L’Oreal Acquires 10% Stake, Plans R&D Collaboration With Galderma

 

L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.